IL-17A treatment influences murine susceptibility to experimental Riemerella anatipestifer infection

Dev Comp Immunol. 2020 May:106:103633. doi: 10.1016/j.dci.2020.103633. Epub 2020 Jan 25.

Abstract

Riemerella anatipestifer causes infectious disease and considerable economic loss in the duck industry worldwide. Our previous studies demonstrated an association between proinflammatory cytokine interleukin (IL)-17A and R. anatipestifer infection. Here, we provide evidence for IL-17A involvement in R. anatipestifer infection using a mouse model. Mice showed higher resistance to R. anatipestifer infection than ducks, with median lethal doses (LD50) of 3.5 × 1010 and 5 × 107 colony-forming units (CFU), respectively. Twenty-four hours after infection, mice with a sub-lethal dose (3.5 × 109 CFU) exhibited levels of IL-17A and IL-23 expression similar to uninfected mice. Thus, we hypothesized that exogenous IL-17A or IL-23 administration affects susceptibility of mice to R. anatipestifer. Mice pretreated with IL-17A or IL-23 prior to sub-lethal dose infection of R. anatipestifer exhibited increased bacterial burden and spleen weights compared to untreated infected mice, confirming the involvement of IL-17A in susceptibility to R. anatipestifer infection in vivo.

Keywords: Ducks; IL-17A; IL-23; Mouse model; Riemerella infection; Susceptibility.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Avian Proteins / genetics*
  • Avian Proteins / metabolism
  • Bacterial Load
  • Disease Susceptibility
  • Ducks
  • Flavobacteriaceae Infections / immunology*
  • Interleukin-17 / metabolism*
  • Interleukin-23 / metabolism
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Models, Animal
  • Poultry Diseases / immunology*
  • Riemerella / physiology*
  • Sepsis / immunology*

Substances

  • Avian Proteins
  • Interleukin-17
  • Interleukin-23

Supplementary concepts

  • Riemerella anatipestifer